The Prognostic Value of PET/CT Following Induction Therapy in Follicular Lymphoma

A new retrospective study demonstrates the prognostic value of PET-CT scans for patients with follicular lymphoma.

Dr. Judith Trotman, reporting at the American Society of Clinical Oncology annual meeting, said that positron emission tomography–computed tomography performed at the end of induction therapy is strongly predictive of both progression-free and overall survival.

Her team analyzed data on 246 PET-CT scans performed following chemoimmunotherapy in three clinical trials. What they found was that patients with 18-fluorodeoxyglucose (FDG) uptake of 4 or greater on the 5-point Deauville scale for postinduction response assessment, had a four times higher risk for disease progression, compared with patients who became PET negative after induction.

At 4.5 years of follow-up, median progression-free survival (PFS) was 16.9 months for patients with a PET uptake of 4 or greater on the scale, versus 74 months for PET-negative patients.

Overall survival at 4.5 years for patients with a higher uptake of FDG PET was 87 percent, compared with 97 percent for patients who were PET negative after induction.

The study results also showed that conventional CT assessment provides only limited additional value, and that "PET-CT applying the 5-point scale should be the new gold standard for therapeutic response assessment in this lymphoma."

Added Dr. Trotman, "We argue that for the patients who remain PET positive, follicular lymphoma is no longer an indolent histology."

Source: ASCO

More Articles

More Articles

This entry looks at what is sometimes referred to as mesenteric lymphoma, also referred to as non-Hodgkin's...

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

B cell lymphoma is not one disease but a few dozen heterogeneous diseases, or individual cancers, that affect the b...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Also known as Hodgkin's disease, Hodgkin's lymphoma (HL) is a cancer of the white blood cells, or...

Canine lymphoma, just like lymphoma in humans, can be separated into stages,...

This article looks at the Non-Hodgkin's Lymphoma survival rate as well as the Non-Hodgkin's Lymphoma mortality rate ....

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

It's not uncommon for patients with some lymphomas to experience itching (clinically known as pruritus). Lymphoma itching symptoms can range from...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...